Disease-modifying antirheumatic drugs in pregnancy: Current status and implications for the future

Drug Safety

Volumn 29, Issue 10, 2006, Pages 845-863

  Vroom, Fokaline ^a   De Walle, Hermien E K ^b   Van De Laar, Mart A J F ^c,d   Brouwers, Jacobus R B J ^a,e   De Jong van Den Berg, Lolkje T W ^a,f  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d UNIVERSITY OF TWENTE   (Netherlands)

^e MEDICAL CENTER LEEUWARDEN   (Netherlands)

^f NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; AURANOFIN; AUROTHIOGLUCOSE; AUROTHIOMALATE; AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; HEPARIN; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NAPROXEN; PENICILLAMINE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE;

BIRTH DEFECT; CONGENITAL MALFORMATION; DOWN SYNDROME; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; EYE TOXICITY; HUMAN; INNER EAR DISEASE; MALARIA; PREGNANCY; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME;

EID: 33749451213     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200629100-00003     Document Type: Review

References (65)

1. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996 May; 39 (5): 723-31
2. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002 Feb; 46 (2): 328-46
3. Mitchell AA. Systematic identification of drugs that cause birth defects: a new opportunity. N Engl J Med 2003 Dec 25; 349 (26): 2556-9
4. Commissie Farmaceutische Hulp van het College voor zorgverzekeringen. Farmacotherapeutisch Kompas; Medisch farmaceutische voorlichting. Amstelveen, 2005
5. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. Sixth edition ed. New York: Lippincott Williams & Wilkins, 2002
6. Current categories for drug use in pregnancy [online]. Available from URL: http://www.fda.gov/fdac/features/2001/301_preg.html [Accessed 2006 Aug 7]
7. Levy M, Buskila D, Gladman DD, et al. Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol 1991 May; 8 (3): 174-8
8. Buchanan NM, Khamashta MA, Morton KE, et al. A study of 100 high risk lupus pregnancies. Am J Reprod Immunol 1992 Oct; 28 (3-4): 192-4
9. Buchanan NM, Toubi E, Khamashta MA, et al. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 1996 Jul; 55 (7): 486-8
10. Parke A, West B. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 1996 Oct; 23 (10): 1715-8
11. Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001; 10 (6): 401-4
12. Klinger G, Morad Y, Westall CA, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 2001 Sep 8; 358 (9284): 813-4
13. Motta M, Tincani A, Faden D, et al. Antimalarial agents in pregnancy. Lancet 2002 Feb 9; 359 (9305): 524-5
14. Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003 Nov; 48 (11): 3207-11
15. Kozlowski RD, Steinbrunner JV, MacKenzie AH, et al. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990 Jun; 88 (6): 589-92
16. Feldkamp M, Carey JC. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology 1993 Jun; 47 (6): 533-9
17. Donnenfeld AE, Pastuszak A, Noah JS, et al. Methotrexate exposure prior to and during pregnancy. Teratology 1994 Feb; 49 (2): 79-81
18. Buckley LM, Bullaboy CA, Leichtman L, et al. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1997 May; 40 (5): 971-3
19. Del Campo M, Kosaki K, Bennett FC, et al. Developmental delay in fetal aminopterin/methotrexate syndrome. Teratology 1999 Jul; 60 (1): 10-2
20. Bawle EV, Conard JV, Weiss L. Adult and two children with fetal methotrexate syndrome. Teratology 1998 Feb; 57 (2): 51-5
21. Giannakopoulou C, Manoura A, Hatzidaki E, et al. Multimodal cancer chemotherapy during the first and second trimester of pregnancy: a case report. Eur J Obstet Gynecol Reprod Biol 2000 Jul; 91 (1): 95-7
22. Ostensen M, Hartmann H, Salvesen K. Low dose weekly methotrexate in early pregnancy: a case series and review of the literature. J Rheumatol 2000 Aug; 27 (8): 1872-5
23. Krahenmann F, Ostensen M, Stallmach T, et al. In utero first trimester exposure to low-dose methotrexate with increased fetal nuchal translucency and associated malformations. Prenat Diagn 2002 Jun; 22 (6): 489-90
24. Nguyen C, Duhl AJ, Escallon CS, et al. Multiple anomalies in a fetus exposed to low-dose methotrexate in the first trimester. Obstet Gynecol 2002 Apr; 99 (4): 599-602
25. Granzow JW, Thaller SR, Panthaki Z. Cleft palate and toe malformations in a child with fetal methotrexate exposure. J Craniofac Surg 2003 Sep; 14 (5): 747-8
26. Chapa JB, Hibbard JU, Weber EM, et al. Prenatal diagnosis of methotrexate embryopathy. Obstet Gynecol 2003 May; 101 (5 Pt 2): 1104-7
27. Lewden B, Vial T, Elefant E, et al. Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study. J Rheumatol 2004 Dec; 31 (12): 2360-5
28. Koyama N, Komori S, Bessho T, et al. Holoprosencephaly in a fetus with maternal medication of sulfasalazine in early gestation: a case report. Clin Exp Obstet Gynecol 1996; 23 (3): 136-40
29. Norgard B, Czeizel AE, Rockenbauer M, et al. Population-based case control study of the safety of sulfasalazine use during pregnancy. Aliment Pharmacol Ther 2001 Apr; 15 (4): 483-6
30. Kallen B. Maternal drug use and infant cleft lip/palate with special reference to corticoids. Cleft Palate Craniofac J 2003 Nov; 40 (6): 624-8
31. Alstead EM, Ritchie JK, Lennard-Jones JE, et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990 Aug; 99 (2): 443-6
32. Ramsey-Goldman R, Mientus JM, Kutzer JE, et al. Pregnancy outcome in women with systemic lupus erythematosus treated with immunosuppressive drugs. J Rheumatol 1993 Jul; 20 (7): 1152-7
33. Heneghan MA, Norris SM, O'Grady JG, et al. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001 Jan; 48 (1): 97-102
34. Norgard B, Pedersen L, Fonager K, et al. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol Ther 2003 Mar 15; 17 (6): 827-34
35. Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003 Jan; 124 (1): 9-17
36. Oefferlbauer-Ernst A, Reinisch W, Miehsler W, et al. Healthy offspring in parents both receiving thiopurines. Gastroenterology 2004 Feb; 126 (2): 628
37. European Medicines Agency, United Kingdom. European public assessment report and product information adaliumab [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/trudexa/trudexa.htm [Accessed 2006 Apr 7]
38. Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004 Dec; 99 (12): 2385-92
39. Srinivasan R. Infliximab treatment and pregnancy outcome in active Crohn's disease. Am J Gastroenterol 2001 Jul; 96 (7): 2274-5
40. Burt MJ, Frizelle FA, Barbezat GO. Pregnancy and exposure to infliximab (anti-tumor necrosis factor-alpha monoclonal antibody). J Gastroenterol Hepatol 2003 Apr; 18 (4): 465-6
41. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 2003 Feb; 30 (2): 241-6
42. European Medicines Agency, United Kingdom. European public assessment report and product information anakinra [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/kineret/kineret.htm [Accessed 2005 Dec 13]
43. European Medicines Agency, United Kingdom. European public assessment report and product information leflunomide [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/arava/arava.htm [Accessed 2005 Dec 13]
44. Ostensen M. Disease specific problems related to drug therapy in pregnancy. Lupus 2004; 13 (9): 746-50
45. Bar OB, Hackman R, Einarson T, et al. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001 Apr 27; 71 (8): 1051-5
46. Enns GM, Roeder E, Chan RT, et al. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? Am J Med Genet 1999 Sep 17; 86 (3): 237-41
47. Vaux KK, Kahole NC, Jones KL. Cyclophosphamide, methotrexate, and cytarabine embropathy: is apoptosis the common pathway? Birth Defects Res A Clin Mol Teratol 2003 Jun; 67 (6): 403-8
48. Zemlickis D, Lishner M, Erlich R, et al. Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide [abstract]. Teratog Carcinog Mutagen 1993; 13 (3): 139-43
49. Medicine Evaluation Board, the Netherlands. Product information aurothioglucose [online]. Available (till 2005 Dec 31) from URL: http://www.cbg-meb.nl/IB-teksten/01328-01338.pdf [Accessed 2005 Dec 13]
50. Medicine Evaluation Board, the Netherlands. Product information auranofin [online]. Available from URL: http://www.cbg-meb.nl/IB-teksten/10719.pdf [Accessed 2006 Apr 7]
51. Medicine Evaluation Board, the Netherlands. Product information gold sodium thiomalate [online]. Available from URL: http://www.cbg-meb.nl/IB- teksten/27387-27388.pdf [Accessed 2005 Dec 13]
52. Nunns D, Hawthorne B, Goulding P, et al. Wilson's disease in pregnancy. Eur J Obstet Gynecol Reprod Biol 1995 Sep; 62 (1): 141-3
53. Soong YK, Huang HY, Huang CC, et al. Successful pregnancy after D-penicillamine therapy in a patient with Wilson's disease [abstract]. J Formos Med Assoc 1991; 90 (7): 693-6
54. Martinez-Frias ML, Rodriguez-Pinilla E, Bermejo E, et al. Prenatal exposure to penicillamine and oral clefts: case report. Am J Med Genet 1998 Mar 19; 76 (3): 274-5
55. Pinter R, Hogge WA, McPherson E. Infant with severe penicillamine embryopathy born to a woman with Wilson disease. Am J Med Genet A 2004 Jul 30; 128 (3): 294-8
56. Furman B, Bashiri A, Wiznitzer A, et al. Wilson's disease in pregnancy: five successful consecutive pregnancies of the same woman. Eur J Obstet Gynecol Reprod Biol 2001 Jun; 96 (2): 232-4
57. Yalaz M, Aydogdu S, Ozgenc F, et al. Transient fetal myelosuppressive effect of D-penicillamine when used in pregnancy [abstract]. Minerva Pediatr 2003; 55 (6): 625-8
58. Berghella V, Steele D, Spector T, et al. Successful pregnancy in a neurologically impaired woman with Wilson's disease. Am J Obstet Gynecol 1997 Mar; 176 (3): 712-4
59. Hartard C, Kunze K. Pregnancy in a patient with Wilson's disease treated with D-penicillamine and zinc sulfate: a case report and review of the literature. Eur Neurol 1994; 34 (6): 337-40
60. Chin RK. Pregnancy and Wilson's disease. Am J Obstet Gynecol 1991 Aug; 165 (2): 488-9
61. Dupont P, Irion O, Beguin F. Pregnancy in a patient with treated Wilson's disease: a case report. Am J Obstet Gynecol 1990 Nov; 163 (5 Pt 1): 1527-8
62. Meijer WM, de Walle HE, Kerstjens-Frederikse WS, et al. Folic acid sensitive birth defects in association with intrauterine exposure to folic acid antagonists. Reprod Toxicol 2005 Jul; 20 (2): 203-7
63. Hernandez-Diaz S, Werler MM, Walker AM, et al. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001 May 15; 153 (10): 961-8
64. Clowse ME, Magder L, Petri M. Cyclophosphamide for lupus during pregnancy. Lupus 2005; 14 (8): 593-7
65. Albrecht J, Meves A, Bigby M. Case reports and case series from Lancet had significant impact on medical literature. J Clin Epidemiol 2005 Dec; 58 (12): 1227-32